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Background: We investigated the feasibility of rapid disc diffusion antibiotic susceptibility testing (rAST) with
reading of inhibition zones after 6 and/or 8 h of incubation for Enterococcus faecalis, Enterococcus faecium,
Pseudomonas aeruginosa and Acinetobacter baumannii. In addition, we evaluated discrimination of resistant
populations from the WT populations at early timepoints and the requirement for clinical breakpoint adaptations
for proper interpretation of rAST data.
Methods: In total, 815 clinical strains [E. faecalis (n"135), E. faecium (n"227), P. aeruginosa (n"295) and
A. baumannii (n"158)] were included in this study. Disc diffusion plates were streaked, incubated and imaged
using the WASPLabTM automation system. WT populations and non-WT populations were defined using epide-
miological cut-offs.
Results and conclusions: rAST at 6 and 8 h was possible for A. baumannii and enterococci with readability of
inhibition zones .90%. Overall categorical agreement of rAST at 6 h with AST at 18 h was 97.2%, 97.4% and
95.3% for E. faecalis, E. faecium and A. baumannii, respectively. With few exceptions, major categorization error
rates were ,1% for A. baumannii, and vancomycin-resistant E. faecium were clearly separated from the WT at
6 h. For P. aeruginosa the average readability of inhibition zones was 68.9% at 8 h and we found an overall cate-
gorical agreement of 94.8%. Adaptations of clinical breakpoints and/or introduction of technical buffer zones,
preferably based on aggregated population data from various epidemiological settings, are required for proper
interpretation of rAST.
Introduction
Owing to increasing antibiotic resistance, drug susceptibility pat-
terns of bacterial pathogens become more and more unpredict-
able and empirical first-line therapy often turns out to be
inadequate.1,2 Rapid disc diffusion antibiotic susceptibility testing
(rAST) would be beneficial for adequate patient care and proper
installation of targeted antimicrobial therapy, significantly improv-
ing clinical outcome and reducing mortality.3–6
Automated antimicrobial susceptibility test devices such as
VITEK-II or PhoenixTM in principle are able to deliver test results
within 8–16 h, but for some species/drug combinations significant
error rates have been demonstrated, e.g. for Pseudomonas aerugi-
nosa and b-lactams such as cefepime, ceftazidime, carbapenems
and piperacillin/tazobactam.7,8 Another weakness of automated
microdilution is a poor sensitivity for important resistance
phenotypes such as VRE or carbapenem-resistant Acinetobacter
baumannii.9,10
Molecular detection of resistance determinants delivers rapid
results but is hampered by the high number of genes to be covered
for adequate sensitivity and by the lack of validated phenotype/
genotype knowledge databases, particularly for P. aeruginosa and
enterococci.11,12 Maintenance of an accurate coverage is a com-
plex task taking into account the geographical differences in the
prevalence of resistance-mediating genes. In addition, the mere
presence of a gene encoding for antibiotic resistance does not nec-
essarily correlate with its phenotypic expression.11
Disc diffusion is an established, accurate and standardized pro-
cedure, which can be adapted to a diagnostic laboratory’s needs.
EUCAST and CLSI recommend an incubation time of 16–18 h for
most species/drug combinations.13,14 In a proof-of-principle study,
we recently demonstrated that automated rAST is feasible.15 We
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here evaluated whether early reading of disc diffusion is possible
for clinical pathogens with a high diversity of intrinsic resistance
mechanisms, namely enterococci, P. aeruginosa and A. baumannii.
The aims of this study were to examine the feasibility of rAST to dis-
criminate important resistance phenotypes from WT populations
and to identify species/drug combinations that need adaptation of
clinical breakpoints (CBPs).
Methods
Clinical isolates
Study isolates were selected covering a range of inhibition zone diameters
from 6 to 40 mm for each species/drug combination tested (Figure S1,
available as Supplementary data at JAC Online). In particular, isolates close
to the CBPs were included. All non-duplicate clinical strains included in this
study were isolated over a 3 year period from 2013 until 2016 in the clinical
microbiology laboratory of the Institute of Medical Microbiology, University
of Zurich. Isolates of the same species were considered duplicate(s) if they
(i) originated from the same patient, and (ii) showed one major and two
minor differences in AST interpretation at maximum. The following num-
bers of clinical isolates were tested: Enterococcus faecalis (n"135),
Enterococcus faecium (n"227), P. aeruginosa (n"295) and A. baumannii
(n"158).
Quality control strains
To control for methodological precision and for calibration to EUCAST CBPs,
E. faecalis ATCC 29212 and P. aeruginosa ATCC 27853 EUCAST quality con-
trol (QC) strains were tested daily from individual fresh subcultures and indi-
vidually prepared 0.5 McFarland standards. Interpretation was done
according to EUCAST QC tables version 6.1.16 QC ranges and targets were
fulfilled during this study (data not shown).
Definition of phenotypes
Resistance phenotypes and the WT populations were defined using EUCAST
epidemiological cut-offs (ECOFFs; Table S1).17 Prior to conducting this study
drug susceptibility was assigned on the basis of independent disc diameter
measurements applying the EUCAST recommended method on Mueller–
Hinton II agar (Beckon-Dickinson, Franklin Lakes, NJ, USA) using antibiotic
discs from i2a (Montpellier, France) and automated recording using the
SirSCANTM/SirWebTM system (i2a).
We screened for vancomycin resistance in enterococci according to the
EUCAST guidelines using a 24 h incubation period.18 Briefly, isolates of
E. faecalis and E. faecium with vancomycin inhibition zone diameters
12 mm and sharp zone edges were considered vancomycin susceptible,
i.e. WT. Isolates with vancomycin inhibition zones ,12 mm, isolates with
fuzzy zone edges (regardless of the inhibition zone diameter) or isolates
with colonies within the inhibition zone were subjected to PCR assays tar-
geting vanA and vanB to confirm the vancomycin-resistant phenotype.19
For clinical isolates of E. faecalis with an ampicillin non-WT phenotype, iden-
tification was reconfirmed from the AST plate.
Automated susceptibility testing
Susceptibility testing was performed as described previously according to
EUCAST guidelines version 6.0, which are essentially the same as that of CLSI
2016 for the organisms of this study.13–15 In brief, bacterial suspensions were
manually adjusted to a turbidity equivalent to that of a 0.5 McFarland stand-
ard and processed within 15 min. Mueller–Hinton II agar plates (Oxoid
Limited, Basingstoke, UK) were processed in the fully automated WASPTM
(Copan Italia, S.p.A., Brescia, Italy), i.e. plates were each inoculated with 60lL
of the bacterial suspension and streaked automatically. Antibiotic discs of a
single production lot (Oxoid Limited) were placed using a standard distributor,
which was handled by a WASPTM AST robot immediately after plate streaking.
Subsequently, plates were automatically transported to and incubated in a
WASPLabTM incubator (Copan) at 36+2 C in ambient air. Images were taken
after 6, 8, 12 and 18 h of incubation under continuous temperature condi-
tions. Diameter measurements were automatically done by the WASPLabTM
reading software (Copan) and were, if necessary, adjusted on-screen by an
experienced technician.
Statistical analyses
All statistical analyses were performed using R, version 3.2.3.20 The R pack-
age pROC, version 1.8, was used to calculate areas under the receiver oper-
ating characteristic curve and associated confidence intervals.21
To quantify the separability of the WT and non-WT populations, the
maximal accuracy (i.e. the maximal fraction of true predictions) achievable
by a cut-off was calculated based on the prevalences in our dataset.
Results
Readability
Readability was defined as the percentage of data points for which
a diameter measurement could reliably be determined for a given
species/drug combination.
Enterococci
For E. faecalis and E. faecium the average readability was.90% at
6 h,.95% at 8 h and.99% at 12 h (Table 1).
Non-fermenters
Average readability for A. baumannii was 99.2% at 6 h and 100%
at 8 and 12 h. For P. aeruginosa inhibition zone diameters were not
readable reliably at 6 h, but were readable for 68.9% of all isolates
at 8 h and for 93.4% of all isolates at 12 h (Table 1).
Categorical agreement and interpretation errors
Compared with 12 h, categorical agreement at 6–8 h with interpre-
tation at 18 h varied for different species/drug combinations.
Enterococci
Average agreement for E. faecalis and E. faecium was 97.2% and
97.4% at 6 h and 97.6% and 95.4% at 8 h (Table 1). For E. faecalis
categorical agreement at 6 h ranged from 91.3% for gentamicin to
100% for vancomycin, and for E. faecium categorical agreement
at 6 h ranged from 93.1% for gentamicin to 100% for norfloxacin
(Table 1). The highest interpretation error rates in both enterococ-
cal species were observed for gentamicin [very major error (vME)
rates of up to 8.7%].
Non-fermenters
For P. aeruginosa categorical agreement was 94.8% at 8 h and
97.3% at 12 h (Table 1). Average categorical agreement for
A. baumannii was 95.3% at 6 h and 99.9% at 8 h. For P. aeruginosa
categorical agreement at 8 h ranged from 89.2% for meropenem to
99% for tobramycin and gentamicin, and for A. baumannii categori-
cal agreement at 6 h ranged from 87.8% for amikacin to 99.4% for
gentamicin (Table 1). Except for meropenem, categorical agreement
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for P. aeruginosa at 8 h was .90% for b-lactams (piperacillin/tazo-
bactam, ceftazidime, cefepime and imipenem), ciprofloxacin and
the aminoglycosides (amikacin, gentamicin and tobramycin). vME
and ME rates for A. baumannii were low (,1%) at 6 h for the majority
of drugs and no ME and vME were observed for A. baumannii at 8 h
(Table 1).
Discrimination of non-WT and WT populations
Enterococci
WT and non-WT populations were well separated at 6 and 8 h for
all examined species/drug combinations including vancomycin-
resistant E. faecium (n" 62; Table 2 and Figure S1).
Non-fermenters
A. baumannii and P. aeruginosa WT and non-WT populations were
well separated at early timepoints (.95%) for most species/drug
combinations, except for P. aeruginosa and the b-lactams, in par-
ticular imipenem (Table 2 and Figure S1).
Change of zone diameters and putative ECOFFs during
the incubation period
In general, the change of zone diameter was only minor during
the incubation period. For 12 of 24 species/drug combinations the
ECOFF increased over time (Figure 1). For 11 species/drug combina-
tions, the inhibition zone diameters of the WT population did not
Table 1. Readability and categorical agreement of early zone reading after 6, 8 and 12 h as compared with standard incubation at 18–24 h
Zone diameter measurements and related classification parameters (all values in %)
6 versus 18 h 8 versus 18 h 12 versus 18 h
readability
categorical
agreement vME ME mE readability
categorical
agreement vME ME mE readability
categorical
agreement vME ME mE
E. faecalis, n"135
ampicillin 92.6 99.2 0.0 0.0 0.8 97.8 98.5 0.0 0.0 1.5 99.3 98.5 0.0 0.0 1.5
gentamicin 93.3 91.3 8.7 0.0 0.0 97.8 93.2 6.8 0.0 0.0 99.3 100.0 0.0 0.0 0.0
norfloxacin 94.1 98.4 1.6 0.0 0.0 98.5 98.5 1.5 0.0 0.0 100.0 100.0 0.0 0.0 0.0
vancomycin 93.3 100.0 0.0 0.0 0.0 97.8 100.0 0.0 0.0 0.0 99.3 100.0 0.0 0.0 0.0
averageb 93.3 97.2 2.6 0.0 0.2 98.0 97.6 2.1 0.0 0.4 99.5 99.6 0.0 0.0 0.5
E. faecium, n"227
ampicillin 100.0 99.1 0.0 0.0 0.9 100.0 99.1 0.0 0.0 0.9 100.0 99.1 0.0 0.0 0.9
gentamicin 83.3 93.1 6.9 0.0 0.0 98.7 85.7 14.3 0.0 0.0 100.0 98.2 1.8 0.0 0.0
norfloxacin 93.4 100.0 0.0 0.0 0.0 99.6 99.1 0.9 0.0 0.0 100.0 100.0 0.0 0.0 0.0
vancomycin 89.4 97.5 2.5 0.0 0.0 98.2 97.8 2.2 0.0 0.0 100.0 99.1 0.9 0.0 0.0
average 91.5 97.4 2.4 0.0 0.2 99.1 95.4 4.3 0.0 0.2 100.0 99.1 0.7 0.0 0.2
P. aeruginosa, n"295a
piperacillin/tazobactam 68.5 95.5 2.5 2.0 0.0 92.9 96.7 3.3 0.0 0.0
cefepime 68.5 95.5 2.5 2.0 0.0 93.6 97.5 2.5 0.0 0.0
ceftazidime 68.8 95.1 2.5 2.5 0.0 93.2 95.6 3.6 0.7 0.0
imipenem 67.5 93.5 1.5 0.0 5.0 93.2 97.1 0.7 0.0 2.2
meropenem 69.2 89.2 0.0 0.0 10.8 92.9 95.6 0.4 0.0 4.0
gentamicin 69.8 99.0 0.5 0.5 0.0 93.6 99.3 0.7 0.0 0.0
tobramycin 69.8 99.0 1.0 0.0 0.0 93.6 98.9 1.1 0.0 0.0
amikacin 67.8 96.5 0.0 0.0 3.5 93.6 98.2 0.0 0.0 1.8
ciprofloxacin 69.8 90.3 0.0 9.7 0.0 93.6 96.7 0.0 3.3 0.0
average 68.9 94.8 1.2 1.9 2.1 93.4 97.3 1.4 0.4 0.9
A. baumannii, n"158
imipenem 99.4 98.7 0.6 0.0 0.6 100.0 99.4 0.0 0.0 0.6 100.0 99.4 0.0 0.0 0.6
meropenem 99.4 91.7 0.6 0.0 7.6 100.0 100.0 0.0 0.0 0.0 100.0 99.4 0.0 0.0 0.6
gentamicin 99.4 99.4 0.0 0.6 0.0 100.0 100.0 0.0 0.0 0.0 100.0 100.0 0.0 0.0 0.0
tobramycin 99.4 96.8 0.0 3.2 0.0 100.0 100.0 0.0 0.0 0.0 100.0 100.0 0.0 0.0 0.0
amikacin 98.7 87.8 0.0 0.6 11.5 100.0 100.0 0.0 0.0 0.0 100.0 100.0 0.0 0.0 0.0
ciprofloxacin 98.7 98.1 0.0 1.9 0.0 100.0 100.0 0.0 0.0 0.0 100.0 100.0 0.0 0.0 0.0
levofloxacin 99.4 94.9 0.0 0.6 4.5 100.0 100.0 0.0 0.0 0.0 100.0 100.0 0.0 0.0 0.0
average 99.2 95.3 0.2 1.0 3.5 100.0 99.9 0.0 0.0 0.1 100.0 99.8 0.0 0.0 0.2
mE, minor error.
Readability was defined as the percentage of clinical isolates for which a zone diameter after a given incubation time could be determined; vME and
ME rates .1% and mE with values .5% are shown in bold.
aCategorical agreement at 6 h and error rates were not calculated due to low readability (average readability 9.2%).
bAverage values are shown in italics.
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change during the incubation period, and for one combination
diameters decreased over time (E. faecium and gentamicin).
Discussion
We recently demonstrated in a proof-of-principle study the
feasibility of rAST.15 E. faecalis, E. faecium, P. aeruginosa and
A. baumannii represent a significant part of microorganisms iso-
lated from critically ill patients. We here evaluated whether early
reading of disc diffusion can be applied to these pathogens. As
reading times 6, 8 and 12 h were chosen in comparison with stand-
ard 18 h evaluation.
Readability at early timepoints differed for the species studied:
on average, zone diameters of A. baumannii and enterococci were
readable for .99% and .90% of isolates after 6 h, respectively.
P. aeruginosa showed an average readability of 68.9% at 8 h and
93.4% at 12 h (Table 1). Extended incubation times related to
insufficient growth of P. aeruginosa have also been reported in
automated antimicrobial susceptibility test devices.22
For A. baumannii, WT and non-WT populations were well sepa-
rated at 6 and 8 h (Table 2 and Figure S1). When applying the 18 h
EUCAST CBPs, ME rates (false-resistant results) of .1% were only
seen for ciprofloxacin and tobramycin at 6 h and average vME rates
(false-susceptible results) were 0.2% at 6 h and 0% at 8 h.
Therefore, early reading and categorization of A. baumannii zone
diameters is well feasible at 6 and 8 h applying current 18 h
EUCAST CBPs.
For P. aeruginosa, we in general observed a good separation of
WT and non-WT populations at early 8 h reading (Table 2 and
Figure S1). For piperacillin/tazobactam, ceftazidime and imipenem
we observed less well separation of WT and non-WT populations,
resulting in categorization error rates ranging from 0.5% to 9.7%
when applying current 18 h EUCAST CBPs (Table 1). An upcoming
task will be the development of species-specific CBPs for early
reading timepoints. In addition, rAST of P. aeruginosa may need
zones of methodological uncertainty that will cover the diameter
overlap of WT and non-WT populations and that will serve as buf-
fer zones to prevent categorization errors. Most clinical strains of
P. aeruginosa display zone diameters that are outside the zone of
overlap and can therefore be assigned to the susceptible/WT or
the resistant/non-WT population. Ruling out resistance will be pos-
sible for a significant number of strains and facilitate proper
decision-making for initial antibiotic therapy.
For enterococci, non-WT and WT populations were well sepa-
rated at early reading times (Table 2 and Figure S1). When current
18 h EUCAST CBPS were applied vME rates of 8.7% and 1.6% for
E. faecalis and gentamicin and norfloxacin at 6 h were observed.
For E. faecium, we found vME rates of 6.9% and 2.5% for
Table 2. Maximal accuracy (in %) for the separation of non-WT and WT populations; cut-offs achieving maximal accuracy are given in parentheses
and prevalences were taken from our dataset
Organism Antibiotic
Maximal accuracya (in %) for the separation of non-WT and WT populations (cut-off) (mm)
6 h 8 h 12 h 18 h
E. faecalis ampicillin 99.2 (8) 99.2 (11) 100 (11) 100 (10)
E. faecalis gentamicin 96.8 (13) 97.7 (11) 98.5 (8) 99.3 (9)
E. faecalis norfloxacin 100 (14) 100 (14) 100 (13) 100 (12)
E. faecium ampicillin 100 (11) 100 (12) 100 (12) 100 (11)
E. faecium gentamicin 98.9 (11) 99.1 (11) 99.6 (9) 100 (8)
E. faecium norfloxacin 100 (15) 100 (15) 100 (14) 100 (13)
E. faecium vancomycin 98 (13) 98.2 (13) 99.1 (11) 100 (11)
P. aeruginosa piperacillin/tazobactam NA 96 (16) 96.7 (18) 100 (18)
P. aeruginosa cefepime NA 95.5 (19) 98.2 (20) 100 (19)
P. aeruginosa ceftazidime NA 95.6 (16) 95.6 (17) 100 (17)
P. aeruginosa imipenem NA 86.9 (20) 93.8 (25) 100 (25)
P. aeruginosa meropenem NA 95.1 (21) 96.7 (24) 100 (24)
P. aeruginosa gentamicin NA 99.5 (14) 99.3 (15) 100 (15)
P. aeruginosa tobramycin NA 100 (17) 98.9 (16) 100 (16)
P. aeruginosa amikacin NA 98 (15) 99.3 (18) 100 (18)
P. aeruginosa ciprofloxacin NA 97.6 (22) 95.3 (25) 100 (25)
A. baumannii imipenem 98.7 (20) 100 (24) 100 (24) 100 (24)
A. baumannii meropenem 98.7 (15) 100 (21) 100 (22) 100 (22)
A. baumannii gentamicin 99.4 (16) 100 (16) 100 (16) 100 (16)
A. baumannii tobramycin 99.4 (14) 100 (15) 100 (15) 100 (14)
A. baumannii amikacin 99.4 (17) 100 (18) 100 (18) 100 (18)
A. baumannii ciprofloxacin 100 (17) 100 (18) 100 (18) 100 (18)
A. baumannii levofloxacin 99.4 (19) 100 (20) 100 (20) 100 (19)
NA, not applicable.
aMaximal accuracy as a measure for separation of two populations requires cut-offs. Using a definitory approach, cut-offs for the different incubation
period/species/antibiotic combinations were set and the maximum accuracy of the separation was calculated (in %).
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Δ = d18h – d6h decrease (D < –2 mm)
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Figure 1. Graphs depict the fifth percentile of the WT population. This value was used as surrogate for the ECOFF as it indicates the lower end of the
WT population. Increasing values (lines with filled circles) or decreasing values (lines with asterisks) depict absolute diameter changes of.2 mm
between 6 and 18 h. Stable values (absolute diameter changes of2 mm between 6 and 18 h) are displayed as lines with diamonds.
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gentamicin and vancomycin at 6 h, respectively (Table 1).
Incubation period-adapted CBPs or zones of methodological
uncertainty will improve categorization into WT and non-WT phe-
notypes. This is of particular relevance for VRE, as 3 of 65 VRE clini-
cal isolates would have been missed when using the 24 h-based
CBP. The current EUCAST 24 h vancomycin S/,R CBP is 12 mm.
If, e.g. vancomycin diameters of 12–13 mm were considered
inconclusive at 6 or 8 h, the rate of vME in E. faecium would drop
from 2.5% to 0%.
In conclusion, this study demonstrates that rAST, with reading
at 6 h, is possible for A. baumannii, E. faecalis and E. faecium. Only
few CBP changes and/or buffer zones will be needed to avoid ME
and vME. In addition, rAST with reading after 8 h is possible for
P. aeruginosa, but it will require buffer zones, covering the overlap
of WT and non-WT populations, to prevent erroneous categoriza-
tions, in particular for the b-lactams. As a further limitation, this
single-centre study cannot issue generally applicable CBPs for
rAST, as aggregated population data from various epidemiological
settings are recommended for proper CBP determination. We con-
clude that rAST at 6 or 8 h is feasible for important drug classes for
A. baumannii, E. faecalis and E. faecium, and with some limitations
for P. aeruginosa.
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